ArticleThe Journal of biological chemistry2025
Degradation of CaMKII is stimulated by its active conformation.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Deubiquitinase UCHL1 Drives Susceptibility to Atrial Fibrillation by Stabilizing CaMKII-δ.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Sustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging.Aging cell · 2026Article
- Discovery of a novel CaMKⅡα inhibitor by machine learning, molecular docking and molecular dynamics simulation.Journal of computer-aided molecular design · 2026Article
- ESCRT-0 regulates AMPA receptor currents and CabioRxiv : the preprint server for biology · 2026Article
- Genetic analyses enabled by the fourth chromosome resource project reveal unexpected mutant phenotypes and suggest new disease models.G3 (Bethesda, Md.) · 2026Article
- Activity drives local CaMKII synthesis and subcellular localization via autophosphorylation-dependent pathways.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Maintaining synaptic protein levels that support both functional stability and plasticity is crucial for the proper function of the nervous system. Calcium/calmodulin-dependent protein kinase II (CaMKII) plays a pivotal role in synaptic signaling, with its synaptic levels regulated by both activity-dependent translocation from the cytosol and local translation. However, the mechanisms governing the removal of CaMKII from synapses and its degradation remain poorly understood. In this study, we develop a HEK293T cell culture system to investigate what properties of CaMKII regulate its degradation. By isolating distinct conformational states of both Drosophila and rat CaMKII, we demonstrate that locking CaMKII in its active form via a phosphomimetic mutation at the autonomous activation site significantly reduces the half-life for both homologs. We identify ubiquitination as the primary degradation pathway for persistently active CaMKII mutants. Moreover, our findings suggest that the decreased half-life is primarily due to the exposure of the catalytic and regulatory domains, rather than changes in the oligomerization state of the holoenzyme or regulation of degradation pathways by the kinase's enzymatic activity. These results provide a template for understanding CaMKII degradation in neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.